Cancer

Whitehead Institute’s physician-scientists—researchers who also practice medicine—are highly motivated by the goal of improving patients’ outcomes. What drew them to Whitehead Institute is the possibility of making paradigm-shifting discoveries that can lead to major advances in medicine.

Cancer cells decorate themselves with the CD47 protein, signaling the immune system to stand down. Whitehead Institute Valhalla Fellow Kipp Weiskopf and colleagues have developed a novel drug screen, pinpointing which cancer therapies — when combined with CD47-blocking antibodies — fare best at rallying the immune system against lung cancer cells.

Sunny Das is a postdoc in Whitehead Institute Member Robert Weinberg’s lab studying how breast cancer metastasizes or spreads to other tissues. We sat down with Sunny to learn more about him and his experiences in and out of the lab.

Eric Smith is a postdoc in Whitehead Institute Member Iain Cheeseman’s lab studying proteins involved in cancer. We sat down with Eric to learn more about him and his experiences in and out of the lab.

Tobiloba Oni and Kipp Weiskopf are Valhalla Fellows at Whitehead Institute who are researching ways to harness our natural defenses to combat cancer, an approach called immunotherapy.

Researchers in Whitehead Institute Member Robert Weinberg’s lab identified two molecules active in cancer stem cells that control whether the cells can form new tumors.

Family trees of lung cancer cells, built using CRISPR-based lineage tracing, reveal in depth how cancer evolves from its earliest stages to become aggressive and capable of spreading throughout the body.

New research from the lab of Whitehead Institute Founding Member Robert Weinberg shows that cells change in diverse ways through the actions of the epithelial-mesenchymal transition, which can influence whether cells are able to form new tumors after they spread.

Kipp Weiskopf—who is identifying ways to prompt macrophages to fight cancer—has been named a Valhalla Fellow.